SL Bio Commences Trading on Nasdaq as SLBT
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Newsfilter
- Business Combination Completed: SL Bio's merger with Horizon Space Acquisition II Corp. was finalized on June 12, 2026, resulting in an implied valuation of approximately $5.568 billion, marking a significant strategic expansion in the biomedical sector.
- Funding for Innovative Therapies: The transaction includes a $7.8 million PIPE financing aimed at advancing SL Bio's proprietary Gamma delta T cell-based therapies, particularly for clinical trials targeting pancreatic and brain cancers, which is expected to significantly enhance treatment accessibility and efficiency.
- Enhanced Executive Team: The leadership team of SL Bio has been strengthened with seasoned executives and independent directors, including CEO William Wang and CFO Ray Leung, ensuring effective compliance and driving business growth post-Nasdaq listing.
- Global Market Access: Listing on Nasdaq provides SL Bio direct access to U.S. institutional capital markets, enhancing financial flexibility to attract top-tier global scientific talent and facilitate future strategic acquisitions and global licensing partnerships.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HSPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HSPT
About HSPT
Horizon Space Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The Company’s efforts to identify a prospective target business will not be limited to a particular industry or geographic region. It has not selected any target business for its initial business combination. The Company has neither engaged in any operations nor generated any revenues.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SL Bio Commences Trading on Nasdaq as SLBT
- Business Combination Completed: SL Bio's merger with Horizon Space Acquisition II Corp. was finalized on June 12, 2026, with an implied valuation of approximately $5.568 billion, and the company is set to trade under the ticker symbol 'SLBT' on Nasdaq starting June 15, 2026, marking a significant milestone in its capital market journey.
- Funding for Innovative Therapies: The transaction, alongside a $7.8 million PIPE financing, provides essential capital to advance SL Bio's proprietary Gamma delta T cell-based therapies through clinical trials targeting pancreatic and brain cancers, which is expected to significantly enhance treatment accessibility and efficiency.
- Enhanced Leadership Team: The leadership team of SL Bio has been strengthened with seasoned executives and independent directors, including CEO William Wang and CFO Ray Leung, ensuring effective compliance and driving business growth post-IPO.
- Global Market Opportunities: Listing on Nasdaq grants SL Bio direct access to U.S. institutional capital markets, enhancing its ability to attract top-tier global scientific talent and laying the groundwork for future strategic acquisitions and global licensing partnerships.
See More
SL Bio Commences Trading on Nasdaq as SLBT
- Business Combination Completed: SL Bio's merger with Horizon Space Acquisition II Corp. was finalized on June 12, 2026, resulting in an implied valuation of approximately $5.568 billion, marking a significant strategic expansion in the biomedical sector.
- Funding for Innovative Therapies: The transaction includes a $7.8 million PIPE financing aimed at advancing SL Bio's proprietary Gamma delta T cell-based therapies, particularly for clinical trials targeting pancreatic and brain cancers, which is expected to significantly enhance treatment accessibility and efficiency.
- Enhanced Executive Team: The leadership team of SL Bio has been strengthened with seasoned executives and independent directors, including CEO William Wang and CFO Ray Leung, ensuring effective compliance and driving business growth post-Nasdaq listing.
- Global Market Access: Listing on Nasdaq provides SL Bio direct access to U.S. institutional capital markets, enhancing financial flexibility to attract top-tier global scientific talent and facilitate future strategic acquisitions and global licensing partnerships.
See More
Horizon Space Acquisition II Corp. Updates on SL BIO Business Combination Process
- Redemption Process Clarification: HSPT has clarified the redemption process for shareholders regarding the business combination with SL BIO, requiring instructions to the transfer agent by 5 PM ET on February 11, 2026, to ensure shares are redeemed if the business combination or extension proposals are implemented.
- Meeting Confirmation: The business combination meeting is scheduled for 9 AM on February 12, 2026, with a redemption deadline of 5 PM on February 10, ensuring shareholders can participate in voting at the Robinson & Cole LLP office in New York.
- Shareholder Voting Rights: Shareholders as of the record date of December 29, 2025, retain voting rights even if shares are sold afterward, encouraging those who have not yet voted to act promptly to ensure their voices are heard.
- Risk Advisory: The company warns shareholders of potential risks, including the possibility of the merger not closing, emphasizing the importance of reviewing relevant documents to understand all details and implications of the merger.
See More
SL BIO and HSPT Merger Approved by SEC, Expected Nasdaq Listing
- Merger Progress: The registration statement for the merger between SL BIO and HSPT was approved by the SEC on January 13, 2026, marking a significant step towards SL BIO becoming a public company, which is expected to enhance its financing capabilities and market influence.
- Shareholder Meeting Scheduled: HSPT plans to hold a special shareholder meeting on February 3, 2026, to vote on the merger proposal, which, if approved, will pave the way for SL BIO's listing and further strengthen its competitive position in the biomedicine sector.
- New Company Structure: Post-merger, SL Science Holding Limited will become the new holding company, expected to be listed on Nasdaq under the ticker symbol “SLBT,” providing SL BIO with broader access to capital markets to support its R&D and market expansion.
- Innovative Technology Potential: SL BIO focuses on developing cellular and gene therapies using immune stem cells and bovine-derived milk exosomes, which are anticipated to drive breakthroughs in regenerative medicine and cancer treatment, presenting significant market prospects and strategic importance.
See More
Saks Global Enterprises Faces Bankruptcy Risk, Seeks Capital Injection to Stay Afloat
- Financial Crisis: Barely a year after acquiring Neiman Marcus for $2.65 billion, Saks Global Enterprises is facing potential bankruptcy, with lenders discussing capital injections to keep the luxury department store empire operational.
- Supply Chain Issues: Vendors have begun slowing shipments due to Saks falling behind on payments, and the company’s request to extend overdue bills over a year has negatively impacted its reputation as a luxury retailer.
- Acquisition Risks: Moody's has flagged the acquisition loans as highly risky, expressing doubts about the combined company's viability, which reflects market concerns regarding its future performance.
- Strategic Challenges: Although the plan was to revive Saks and its brands through cost-cutting and tech upgrades, the actual execution has faced a crisis of trust with suppliers, potentially hindering future business recovery.
See More
SL Bio to Merge with Horizon Space Acquisition II at $5.7 Billion Valuation, Plans 2026 Listing
- Merger Overview: Taiwan-based SL Bio Ltd. has entered into a merger agreement with Horizon Space Acquisition II Corp, with an implied equity valuation of approximately $5.7 billion, marking a strategic shift for the company to enter the U.S. market via SPAC.
- Listing Path Preference: This merger reflects the biotechnology sector's preference for SPAC transactions, particularly as traditional IPOs face challenges, enabling SL Bio to secure long-term capital and enhance market visibility.
- Focus on R&D: SL Bio is concentrating on advanced cellular and gene therapy technologies, developing immunotherapies for high-need oncology indications such as blood cancers, pancreatic cancer, and brain tumors, showcasing its market potential in critical therapeutic areas.
- Future Outlook: The combined entity is expected to go public in early 2026, and if successful, will provide U.S. investors with direct exposure to SL Bio, further enhancing its influence in the biotechnology sector.
See More
SL Bio Commences Trading on Nasdaq as SLBT
- Business Combination Completed: SL Bio's merger with Horizon Space Acquisition II Corp. was finalized on June 12, 2026, with an implied valuation of approximately $5.568 billion, and the company is set to trade under the ticker symbol 'SLBT' on Nasdaq starting June 15, 2026, marking a significant milestone in its capital market journey.
- Funding for Innovative Therapies: The transaction, alongside a $7.8 million PIPE financing, provides essential capital to advance SL Bio's proprietary Gamma delta T cell-based therapies through clinical trials targeting pancreatic and brain cancers, which is expected to significantly enhance treatment accessibility and efficiency.
- Enhanced Leadership Team: The leadership team of SL Bio has been strengthened with seasoned executives and independent directors, including CEO William Wang and CFO Ray Leung, ensuring effective compliance and driving business growth post-IPO.
- Global Market Opportunities: Listing on Nasdaq grants SL Bio direct access to U.S. institutional capital markets, enhancing its ability to attract top-tier global scientific talent and laying the groundwork for future strategic acquisitions and global licensing partnerships.
See More
SL Bio Commences Trading on Nasdaq as SLBT
- Business Combination Completed: SL Bio's merger with Horizon Space Acquisition II Corp. was finalized on June 12, 2026, resulting in an implied valuation of approximately $5.568 billion, marking a significant strategic expansion in the biomedical sector.
- Funding for Innovative Therapies: The transaction includes a $7.8 million PIPE financing aimed at advancing SL Bio's proprietary Gamma delta T cell-based therapies, particularly for clinical trials targeting pancreatic and brain cancers, which is expected to significantly enhance treatment accessibility and efficiency.
- Enhanced Executive Team: The leadership team of SL Bio has been strengthened with seasoned executives and independent directors, including CEO William Wang and CFO Ray Leung, ensuring effective compliance and driving business growth post-Nasdaq listing.
- Global Market Access: Listing on Nasdaq provides SL Bio direct access to U.S. institutional capital markets, enhancing financial flexibility to attract top-tier global scientific talent and facilitate future strategic acquisitions and global licensing partnerships.
See More
Horizon Space Acquisition II Corp. Updates on SL BIO Business Combination Process
- Redemption Process Clarification: HSPT has clarified the redemption process for shareholders regarding the business combination with SL BIO, requiring instructions to the transfer agent by 5 PM ET on February 11, 2026, to ensure shares are redeemed if the business combination or extension proposals are implemented.
- Meeting Confirmation: The business combination meeting is scheduled for 9 AM on February 12, 2026, with a redemption deadline of 5 PM on February 10, ensuring shareholders can participate in voting at the Robinson & Cole LLP office in New York.
- Shareholder Voting Rights: Shareholders as of the record date of December 29, 2025, retain voting rights even if shares are sold afterward, encouraging those who have not yet voted to act promptly to ensure their voices are heard.
- Risk Advisory: The company warns shareholders of potential risks, including the possibility of the merger not closing, emphasizing the importance of reviewing relevant documents to understand all details and implications of the merger.
See More
SL BIO and HSPT Merger Approved by SEC, Expected Nasdaq Listing
- Merger Progress: The registration statement for the merger between SL BIO and HSPT was approved by the SEC on January 13, 2026, marking a significant step towards SL BIO becoming a public company, which is expected to enhance its financing capabilities and market influence.
- Shareholder Meeting Scheduled: HSPT plans to hold a special shareholder meeting on February 3, 2026, to vote on the merger proposal, which, if approved, will pave the way for SL BIO's listing and further strengthen its competitive position in the biomedicine sector.
- New Company Structure: Post-merger, SL Science Holding Limited will become the new holding company, expected to be listed on Nasdaq under the ticker symbol “SLBT,” providing SL BIO with broader access to capital markets to support its R&D and market expansion.
- Innovative Technology Potential: SL BIO focuses on developing cellular and gene therapies using immune stem cells and bovine-derived milk exosomes, which are anticipated to drive breakthroughs in regenerative medicine and cancer treatment, presenting significant market prospects and strategic importance.
See More
Saks Global Enterprises Faces Bankruptcy Risk, Seeks Capital Injection to Stay Afloat
- Financial Crisis: Barely a year after acquiring Neiman Marcus for $2.65 billion, Saks Global Enterprises is facing potential bankruptcy, with lenders discussing capital injections to keep the luxury department store empire operational.
- Supply Chain Issues: Vendors have begun slowing shipments due to Saks falling behind on payments, and the company’s request to extend overdue bills over a year has negatively impacted its reputation as a luxury retailer.
- Acquisition Risks: Moody's has flagged the acquisition loans as highly risky, expressing doubts about the combined company's viability, which reflects market concerns regarding its future performance.
- Strategic Challenges: Although the plan was to revive Saks and its brands through cost-cutting and tech upgrades, the actual execution has faced a crisis of trust with suppliers, potentially hindering future business recovery.
See More
SL Bio to Merge with Horizon Space Acquisition II at $5.7 Billion Valuation, Plans 2026 Listing
- Merger Overview: Taiwan-based SL Bio Ltd. has entered into a merger agreement with Horizon Space Acquisition II Corp, with an implied equity valuation of approximately $5.7 billion, marking a strategic shift for the company to enter the U.S. market via SPAC.
- Listing Path Preference: This merger reflects the biotechnology sector's preference for SPAC transactions, particularly as traditional IPOs face challenges, enabling SL Bio to secure long-term capital and enhance market visibility.
- Focus on R&D: SL Bio is concentrating on advanced cellular and gene therapy technologies, developing immunotherapies for high-need oncology indications such as blood cancers, pancreatic cancer, and brain tumors, showcasing its market potential in critical therapeutic areas.
- Future Outlook: The combined entity is expected to go public in early 2026, and if successful, will provide U.S. investors with direct exposure to SL Bio, further enhancing its influence in the biotechnology sector.
See More
